SHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that a Phase II Clinical Trial of Monkeypox Treatment by NV-387 is expected to ...
The National Institutes of Health (NIH) is launching a Phase 3 clinical trial to determine the efficacy of tecovirimat — the smallpox antiviral better known as TPOXX — for use in treating monkeypox, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results